137 related articles for article (PubMed ID: 37572583)
1. Identification of a novel RSRC1-ALK (R6: A20) fusion using next-generation sequencing technique.
Xia J; Chen S; Zhang Z; Wang J
Cancer Genet; 2023 Nov; 278-279():18-23. PubMed ID: 37572583
[TBL] [Abstract][Full Text] [Related]
2. Combinational Analysis of FISH and Immunohistochemistry Reveals Rare Genomic Events in ALK Fusion Patterns in NSCLC that Responds to Crizotinib Treatment.
Li W; Zhang J; Guo L; Chuai S; Shan L; Ying J
J Thorac Oncol; 2017 Jan; 12(1):94-101. PubMed ID: 27614248
[TBL] [Abstract][Full Text] [Related]
3. ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma.
Dacic S; Villaruz LC; Abberbock S; Mahaffey A; Incharoen P; Nikiforova MN
Oncotarget; 2016 Dec; 7(50):82943-82952. PubMed ID: 27769042
[TBL] [Abstract][Full Text] [Related]
4. Detecting anaplastic lymphoma kinase (ALK) gene rearrangements with next-generation sequencing remains a reliable approach in patients with non-small-cell lung cancer.
Ding Y; Sun C; Su W; Miao C; He X; Wang JS; Zhang ZH
Virchows Arch; 2022 Sep; 481(3):405-419. PubMed ID: 35624360
[TBL] [Abstract][Full Text] [Related]
5. Lung adenocarcinoma with a novel SRBD1-ALK Fusion responding to crizotinib.
Chen Y; Zhang X; Jiang Q; Wang B; Wang Y; Junrong Y
Lung Cancer; 2020 Aug; 146():370-372. PubMed ID: 32527613
[TBL] [Abstract][Full Text] [Related]
6. Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.
Ma D; Wang Z; Yang L; Mu X; Wang Y; Zhao X; Li J; Lin D
Oncotarget; 2016 Sep; 7(39):64410-64420. PubMed ID: 27418132
[TBL] [Abstract][Full Text] [Related]
7. Detecting ALK Rearrangement with RT-PCR: A Reliable Approach Compared with Next-Generation Sequencing in Patients with NSCLC.
Kuang Y; Xu P; Wang J; Zheng Y; Sun X; Li Z; Gan R; Li H; Guo Y; Yao F; Zhu C; Ke Z; Tang K
Mol Diagn Ther; 2021 Jul; 25(4):487-494. PubMed ID: 34133003
[TBL] [Abstract][Full Text] [Related]
8. Attenuated isolated 3' signal: A highly challenging therapy relevant ALK FISH pattern in NSCLC.
Smuk G; Pajor G; Szuhai K; Morreau H; Kocsmár I; Kocsmár É; Pajor L; Kajtár B; Sárosi V; Lotz G; Tornóczky T
Lung Cancer; 2020 May; 143():80-85. PubMed ID: 32272316
[TBL] [Abstract][Full Text] [Related]
9. Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer.
Lin C; Shi X; Yang S; Zhao J; He Q; Jin Y; Yu X
Lung Cancer; 2019 May; 131():62-68. PubMed ID: 31027700
[TBL] [Abstract][Full Text] [Related]
10. Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review.
Li M; An Z; Tang Q; Ma Y; Yan J; Chen S; Wang Y
J Cell Mol Med; 2021 Oct; 25(19):9476-9481. PubMed ID: 34541785
[TBL] [Abstract][Full Text] [Related]
11. Molecular characteristics and clinical outcomes of complex ALK rearrangements identified by next-generation sequencing in non-small cell lung cancers.
Xia P; Zhang L; Li P; Liu E; Li W; Zhang J; Li H; Su X; Jiang G
J Transl Med; 2021 Jul; 19(1):308. PubMed ID: 34271921
[TBL] [Abstract][Full Text] [Related]
12. PLEKHM2-ALK: A novel fusion in small-cell lung cancer and durable response to ALK inhibitors.
Li T; Zhang F; Wu Z; Cui L; Zhao X; Wang J; Hu Y
Lung Cancer; 2020 Jan; 139():146-150. PubMed ID: 31794921
[TBL] [Abstract][Full Text] [Related]
13. Identification and therapeutic evaluation of ALK rearrangements in non-small-cell lung cancer.
Zhao R; Guo L; Zhang B; Zhao J; Xiang C; Chen S; Shao J; Zhu L; Ye M; Han Y
J Pathol Clin Res; 2022 Nov; 8(6):538-549. PubMed ID: 35848751
[TBL] [Abstract][Full Text] [Related]
14. A novel SOS1-ALK fusion variant in a patient with metastatic lung adenocarcinoma and a remarkable response to crizotinib.
Chen HF; Wang WX; Xu CW; Huang LC; Li XF; Lan G; Zhai ZQ; Zhu YC; Du KQ; Lei L; Fang MY
Lung Cancer; 2020 Apr; 142():59-62. PubMed ID: 32114282
[TBL] [Abstract][Full Text] [Related]
15. A rare KIF5B-ALK fusion variant in a lung adenocarcinoma patient who responded to crizotinib and acquired the ALK L1196M mutation after resistance: a case report.
Zeng H; Liu Y; Wang W; Tang Y; Tian P; Li W
Ann Palliat Med; 2021 Jul; 10(7):8352-8357. PubMed ID: 33832282
[TBL] [Abstract][Full Text] [Related]
16. Lung adenocarcinoma harboring complex EML4-ALK fusion and BRAF V600E co-mutation responded to alectinib.
Guo W; Liang J; Zhang D; Huang X; Lv Y
Medicine (Baltimore); 2022 Oct; 101(40):e30913. PubMed ID: 36221356
[TBL] [Abstract][Full Text] [Related]
17. A novel SLC8A1/LINC01913 intergenic region-ALK fusion identified by NGS and validated by IHC and FISH in a stage IIB lung adenocarcinoma patient who remains relapse-free during the treatment of crizotinib: a case report.
Wang C; Chen S; He Q; Sun T; Xu P
Invest New Drugs; 2022 Dec; 40(6):1350-1353. PubMed ID: 35666357
[TBL] [Abstract][Full Text] [Related]
18. Custom Gene Capture and Next-Generation Sequencing to Resolve Discordant ALK Status by FISH and IHC in Lung Adenocarcinoma.
Jang JS; Wang X; Vedell PT; Wen J; Zhang J; Ellison DW; Evans JM; Johnson SH; Yang P; Sukov WR; Oliveira AM; Vasmatzis G; Sun Z; Jen J; Yi ES
J Thorac Oncol; 2016 Nov; 11(11):1891-1900. PubMed ID: 27343444
[TBL] [Abstract][Full Text] [Related]
19. Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer.
Rosenbaum JN; Bloom R; Forys JT; Hiken J; Armstrong JR; Branson J; McNulty S; Velu PD; Pepin K; Abel H; Cottrell CE; Pfeifer JD; Kulkarni S; Govindan R; Konnick EQ; Lockwood CM; Duncavage EJ
Mod Pathol; 2018 May; 31(5):791-808. PubMed ID: 29327716
[TBL] [Abstract][Full Text] [Related]
20. CUX1-ALK, a Novel ALK Rearrangement That Responds to Crizotinib in Non-Small Cell Lung Cancer.
Zhang M; Wang Q; Ding Y; Wang G; Chu Y; He X; Wu X; Shao YW; Lu K
J Thorac Oncol; 2018 Nov; 13(11):1792-1797. PubMed ID: 30010043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
